Application of bile-derived exosome miRNA in preparation of diagnostic reagent for acute rejection after liver transplantation

Through the detection of bile-derived exosomal miRNA, especially miR-223, the problem of low specificity and sensitivity in the diagnosis of acute rejection after liver transplantation was solved, efficient early diagnosis was achieved, and the treatment effect was significantly improved.

CN118932044APending Publication Date: 2024-11-12THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411146020.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art has poor specificity and sensitivity in the diagnosis of acute rejection after liver transplantation, and the pathological biopsy is invasive and prone to false negatives, which cannot reflect the histopathological inflammatory process early, resulting in poor treatment effect.

Method used

Bile-derived exosomal miRNAs, especially miR-223, are used as diagnostic markers, and their expression levels are detected by real-time fluorescence quantitative PCR and analyzed in combination with other clinical indicators to improve the specificity and sensitivity of the diagnosis.

Benefits of technology

The diagnosis specificity of miR-223 is 85%, the sensitivity is 90%, and the area under the ROC curve is 0.9475, which significantly improves the early diagnosis ability of acute rejection after liver transplantation, can effectively identify AR patients and improve treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932044A_ABST
    Figure CN118932044A_ABST
Patent Text Reader

Abstract

The invention discloses application of bile-derived exosome miRNA in preparation of a diagnostic reagent for acute rejection after liver transplantation, and belongs to the technical field of biomarker diagnosis. The miR-223 with the most significant difference is selected for expanded sample verification, and a real-time fluorescent quantitative PCR (qRT-PCR) technology is used for verifying that the expression of the miR-223 in the bile exosome of a patient with acute rejection reaction is significantly increased. The specificity of the miR-223 for diagnosing the acute rejection reaction is 85%, the sensitivity is 90%, the area under the curve is 0.9475, the experimental result fully shows that the expression level of the miRNA marker is positively correlated with the incidence rate of the acute rejection reaction after the liver transplantation, and finally, the exosome miR-223 derived from bile can be used as the marker for diagnosing the acute rejection reaction after the liver transplantation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomarker diagnosis, and specifically relates to the application of bile-derived exosome miRNA in the preparation of a diagnostic reagent for acute rejection reaction after liver transplantation. Background Art

[0002] Liver transplantation has become the only effective means of treating end-stage liver disease. Acute rejection (AR) is an important complication that affects transplant liver function and recipient prognosis. The clinical manifestations of AR are atypical and easily confused with other diseases. The specificity and sensitivity of traditional indicators currently used in clinical practice are poor. Pathological biopsy is still the gold standard for the diagnosis of AR, but it has the disadvantages of being invasive, having high false negatives, and having many complications. When pathological examination shows abnormalities, the graft has often been irreversibly damaged and cannot reflect the early inflammatory process revealed by histopathology, and the treatment effect is often poor. Therefore, it is urgent to find molecular markers for the early diagnosis of acute rejection after liver transplantation, which has important clinical significance for improving the efficacy of liver transplantation and improving the quality of life of patients.

[0003] As an important branch of in vitro diagnosis, liquid biopsy diagnoses and monitors tumors and other diseases by capturing and detecting biomarkers in various body fluids. Bile is produced by the liver, flows through the bile duct, is in direct contact with the bile duct and is rich in metabolites related to the metabolic pathways of bile duct epithelial cells. For hepatobiliary diseases, bile is a body fluid that is closer to the pathological source than blood and can contain higher levels of secretion or shedding markers. Bile specimens can be obtained during liver transplantation operations, postoperative T-tube, percutaneous biliary drainage, or retrograde pancreaticocholangiopancreatography and other related operations.

[0004] Studies have shown that exosomes can be used as highly specific biomarkers in liquid biopsies. Exosomes are small membrane vesicles with a diameter of 30-150nm, which contain stable biological information specific to the source cells, such as proteins, mRNA and miRNA, and play an important role in intercellular signal transduction. MiRNA is a non-coding, regulatory small RNA that affects multiple links such as mRNA stability and protein translation initiation and progression, and plays an important regulatory role in various physiological and pathological processes. Exosomal miRNA is relatively stable in bile, and the concentration of related biomarkers in bile specimens is higher than that of other body fluid specimens. It can directly reflect the local inflammatory immune state of the transplanted liver and is almost unaffected by lesions in distant organs. Therefore, bile-derived exosomal miRNA has potential application value in the diagnosis of hepatobiliary-related diseases, especially benign and malignant biliary diseases. However, there are few studies on the use of bile-derived exosomal miRNA as a marker to assist in diagnosis of acute rejection after liver transplantation. Summary of the invention

[0005] In order to find suitable molecular markers for early diagnosis of acute rejection after liver transplantation, the present invention aims to provide a use of bile-derived exosomal miRNA in the preparation of a diagnostic reagent for acute rejection after liver transplantation.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] The bile-derived exosomal miRNA of the present invention is used as a molecular marker for diagnosing acute rejection after liver transplantation. The bile-derived exosomal miRNA is miR-223, and its nucleotide sequence is shown in SEQ ID NO.1.

[0008] Bile-derived exosomes refer to extracellular vesicles extracted from bile. These vesicles are formed by the inward budding of the inner membrane when the multivesicular endosomes in the cells mature, and are secreted outside the cells when they fuse with the cell membrane. Bile-derived exosomal miRNA refers to the microRNA (microRNA, abbreviated as miRNA) contained in the exosomes extracted from bile. These miRNA molecules play an important regulatory role inside and outside the cells, participate in intercellular communication and molecular transport, and are of great significance to the occurrence, development and prognosis of the disease. MiR-223 is a specific microRNA molecule, a type of non-coding RNA, with a length of about 22 nucleotides.

[0009] Furthermore, the nucleotide sequence of the reverse transcription primer of miR-223 is shown in SEQ ID NO.2; the nucleotide sequence of the forward amplification primer of miR-223 is shown in SEQ ID NO.3; and the nucleotide sequence of the reverse amplification primer of miR-223 is shown in SEQ ID NO.4.

[0010] Furthermore, bile-derived exosomes are saucer-like, with an average particle size of 66 nm, and are rich in exosomal characteristic markers such as CD63, CD81 and CD9.

[0011] Furthermore, the expression level of miR-223 was positively correlated with the incidence of acute rejection after liver transplantation.

[0012] Furthermore, miR-223 was analyzed in relation to the rejection activity index (RAI score) of AR patients at the same time, lymphocyte count in peripheral blood, alanine aminotransferase, γ-glutamyl transpeptidase, total bilirubin, albumin, and prothrombin time. The results showed that the level of bile exosome miR-223 was positively correlated with the RAI score of the transplanted liver.

[0013] Preferably, the area under the ROC curve of miR-223 is 0.9475, the specificity is 85%, and the sensitivity is 90%.

[0014] Specificity and sensitivity are important indicators for evaluating diagnostic methods or test performance, and they have important application value in the field of medical diagnosis. Specificity is also called True Negative Rate (TNR), which refers to the proportion of subjects who are correctly judged as not having a disease among all subjects who do not actually have a disease. That is to say, the higher the specificity, the lower the misdiagnosis rate (i.e., the proportion of patients who are actually disease-free but mistakenly judged as having a disease). Sensitivity is also called True Positive Rate (TPR), which refers to the proportion of patients who are correctly judged as having a disease among all cases who actually have a disease. It reflects the ability of diagnostic methods or tests to find patients. That is to say, the higher the sensitivity, the lower the missed diagnosis rate (i.e., the proportion of patients who are actually diseased but mistakenly judged as having no disease). The results of the diagnostic markers of the present invention show that both specificity and sensitivity are maintained at a relatively high level, and in particular, the higher sensitivity indicates that the marker has a higher recognition ability for acute rejection after liver transplantation, which is very meaningful for its early screening. At the same time, the ROC curve is a comprehensive reflection of the accuracy of the diagnostic test. The area under the ROC curve (AUC) in the present invention is greater than 0.9, which also shows that it has excellent performance in diagnosing acute rejection after liver transplantation.

[0015] The present invention also discloses the use of a reagent for detecting the expression level of bile-derived exosome miRNA in the preparation of a diagnostic reagent / kit for acute rejection after liver transplantation. The bile-derived exosome miRNA is miR-223, and its nucleotide sequence is shown in SEQ ID NO.1 (5'-UGUCAGUUUGUCAAAUACCCCA-3').

[0016] Preferably, the miR-223 expression level is positively correlated with the incidence of acute rejection after liver transplantation.

[0017] The present invention also discloses a diagnostic product for acute rejection after liver transplantation, wherein the diagnostic product comprises a reagent for detecting the expression of bile-derived exosome miRNA;

[0018] Among them, the bile-derived exosomal miRNA is miR-223, and its nucleotide sequence is shown in SEQ ID NO.1.

[0019] Preferably, the diagnostic product includes a diagnostic reagent and a diagnostic kit.

[0020] Preferably, the miR-223 expression level is detected by real-time fluorescence quantitative PCR.

[0021] Further preferably, the diagnostic kit comprises relevant reagents and materials suitable for real-time fluorescence quantitative PCR.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention takes bile exosomes as the research object for the first time, successfully extracts exosomes from bile, and screens out let-7e-5p, miR-142-3p, miR-106, and miR-223 in bile, which are significantly different in expression between AR and non-AR groups. At the same time, the present invention selects miR-223 with the most significant difference for expanded sample verification, and uses real-time fluorescence quantitative PCR (qRT-PCR) technology to confirm that miR-223 expression in bile exosomes of AR patients is significantly increased. The specificity of miR-223 for diagnosing AR is 85%, the sensitivity is 90%, and the area under the curve is 0.9475. The experimental results fully show that the expression level of miRNA markers is positively correlated with the incidence of acute rejection after liver transplantation, and finally prove that bile-derived exosomes miR-223 can be used as a marker for diagnosing AR after liver transplantation. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 To isolate and purify the bile exosomes of AR patients;

[0025] Figure 2 Electron micrograph of exosomes purified from bile of AR patients (scale bar 500 nm);

[0026] Figure 3 To measure the diameter of bile exosomes in AR patients using the NanoView fully automated exosome fluorescence detection system;

[0027] Figure 4 Fluorescence images of marker proteins CD63, CD81, and CD9 in bile-derived exosomes from AR patients;

[0028] Figure 5 is the fluorescence expression intensity of marker proteins CD63, CD81 and CD9 in bile-derived exosomes of AR patients;

[0029] Figure 6 Volcano plot of differentially expressed miRNAs in bile-derived exosomes from AR and non-AR patients;

[0030] Figure 7 Exosomal miR-223 derived from bile was differentially expressed between AR and non-AR patients;

[0031] Figure 8 To determine the diagnostic ability of bile-derived exosomal miR-223 for AR by ROC curve analysis;

[0032] Fig. 9KEGG analysis of bile-derived exosomal miRNA target genes that were significantly differentially expressed in AR patients. DETAILED DESCRIPTION

[0033] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0034] It should be noted that the terms "including" and "having" and any variations thereof in the specification and claims of the present invention are intended to cover non-exclusive inclusions. For example, a process, method, system, product or apparatus comprising a series of steps or units is not necessarily limited to those steps or units explicitly listed, but may include other steps or units that are not explicitly listed or inherent to these processes, methods, products or apparatuses.

[0035] The present invention is further described in detail below in conjunction with the accompanying drawings:

[0036] 1. Bile Sample Collection

[0037] 1. All samples in this study were collected with the approval of the unit's medical research ethics committee and the informed consent of the patients. Bile samples were collected from the First Affiliated Hospital of Xi'an Jiaotong University. From January 2022 to January 2024, bile was collected from patients who underwent liver transplantation in the First Affiliated Hospital of Xi'an Jiaotong University. Twenty-six patients were diagnosed with AR by liver biopsy, and the control group consisted of 26 patients (non-AR) who recovered well and had stable liver function after liver transplantation during the same period. The time point for bile collection was within 48 hours after the diagnosis of AR after transplantation (7-58 days after surgery) and before treatment. For non-AR patients, the time point for bile collection was the same postoperative course corresponding to the matched AR patients. Among them: screening group (6 AR patients, 6 non-AR patients), verification group (20 AR patients, 20 non-AR patients). The baseline of the cases is shown in Table 1. There was no statistical difference between the groups in the factors in the table.

[0038] Table 1 Clinical baseline characteristics of the enrolled patients

[0039]

[0040] Inclusion criteria: ① diagnosed with end-stage liver disease, excluding other infectious diseases, and undergoing liver transplantation for the first time; ② taking immunosuppressive drugs prescribed by doctors within 3 months, all of which were prednisone + mycophenolate mofetil + FK506 or cyclosporine; ③ regular review and follow-up after surgery; ④ signing the informed consent form.

[0041] Exclusion criteria: ① hyperacute rejection or chronic rejection; ② other surgical complications such as bleeding, vascular stenosis, vascular thrombosis within 1 month after surgery; ③ infectious diseases such as bacteria, tuberculosis or fungi within 1 month after surgery; ④ chronic metabolic or other wasting diseases; ⑤ patients who were unable to take medication, undergo examinations and follow-up as required after surgery.

[0042] 2. Use a 10 mL centrifuge tube to collect bile samples, centrifuge at 2000g for 15 minutes at room temperature to remove cells and debris, collect the supernatant and store it in a -80℃ ultra-low temperature refrigerator.

[0043] 2. Isolation and identification of bile exosomes

[0044] 1. Isolation of exosomes: thaw 5 mL of bile sample, centrifuge at 500g for 10 minutes at 4°C after thawing, remove precipitated cells and debris, and collect the supernatant; centrifuge at 16500g for 20 minutes at 4°C to further remove cell debris and pass through a 200nm filter; transfer the supernatant to a centrifuge tube, wash with PBS, centrifuge at 120000g for 70 minutes at 4°C, and yellow exosome particles can be obtained at the bottom of the centrifuge tube. The specific steps are as follows: Figure 1 Exosomes were used for immediate RNA sequencing, RNA extraction or resuspended in PBS and stored in a -80°C freezer.

[0045] 2. Identification of exosomes:

[0046] 1) Transmission electron microscopy observation of exosomes was commissioned to Hangzhou Lianchuan Biological Co., Ltd.

[0047] 2) NanoView fully automatic exosome fluorescence detection system characterizes exosomes:

[0048] The sample was diluted with 1× sample diluent. The optimal exosome concentration after dilution was about 1×10 7 -10 8 / mL. Take 50μL of diluted sample and drop it on the pre-scanned chip, seal it with sealing film, and incubate it at room temperature for 16h. Use 1× buffer A to elute at high speed for 3 times, 3min each time, add 250μL of freshly prepared staining solution, protect from light, and slowly incubate on a shaker for 1h. The chip should not hit the hole wall. Use 1× buffer B to elute at high speed for 3 times, 3min each time, and use deionized water to shake and wash for 3min. Clamp both sides of the chip with tweezers, move it horizontally into a culture dish containing deionized water, and wash the chip horizontally in the water until the surface impurities are removed. Clamp both sides of the chip and slowly move the chip out of the water at a 45° angle. It is observed that as the chip is discharged from the water, no water droplets remain on the chip. Place the chip on absorbent paper to dry. On-machine detection, data analysis is performed with the help of capture antibodies, single particle interference reflection imaging sensor (SP-IRIS) technology and labeled fluorescence signals on the chip to complete the characterization of exosomes.

[0049] 3. Exosome RNA Extraction and Sequencing

[0050] 1. Exosome RNA Extraction

[0051] 1) Add 300 μL of lysis buffer A and 37.5 μL of lysis buffer B to 200 μL of resuspension containing purified exosomes.

[0052] 2) Mix thoroughly and incubate at room temperature for 10 min;

[0053] 3) Add 500 μL of 100% ethanol and vortex for 10 seconds;

[0054] 4) Transfer the above liquid to Mini Spin Columns and centrifuge at 6000 rpm for 1 min at room temperature;

[0055] 5) Repeat step 4 until all the liquid is transferred to the adsorption column;

[0056] 6) Add 600 μL of eluent A to the adsorption column and centrifuge at 6000 rpm for 30 seconds at room temperature;

[0057] 7) Repeat step 6, washing twice in total;

[0058] 8) Spin the adsorption column idle, centrifuge at 14000 rpm for 60 s at room temperature; transfer it to another elution tube, add 50 μL of elution solution, and centrifuge at 1800 rpm and 8000 rpm for 60 s and 120 s at room temperature respectively;

[0059] 9) To obtain the maximum recovery efficiency, transfer the eluted buffer back to the adsorption column, let it stand at room temperature for 2 minutes, centrifuge at 2000 rpm for 1 minute, and then centrifuge at 8000 rpm for 2 minutes.

[0060] 2. Exosome RNA Sequencing

[0061] The RNA extracted from bile exosomes of 6 AR patients was mixed into 1 tube for sequencing, and the RNA extracted from bile exosomes of 6 non-AR patients was mixed into 1 tube for sequencing.

[0062] The bile exosome miRNA obtained above was quality checked by Agilent 2100 bioanalyzer, and then the extracted RNA was placed in Illumina Novaseq 6000 for sequencing.

[0063] Sequencing screened out let-7e-5p, miR-142-3p, miR-106, and miR-223 in bile, which showed significant differences in expression between the AR and non-AR groups. Among them, miR-223 was selected for further verification in independent samples according to the principle of the most significant difference.

[0064] 4. Reverse Transcription PCR

[0065] The RNA was reverse transcribed into cDNA using the RT first strand cDNA synthesis kit (Lot#LT203701).

[0066] miRNA reversal system (10 μL): (sterile, enzyme-free, on ice), the specific reaction conditions and reaction system are shown in Table 2 below:

[0067] Table 2

[0068]

[0069] 5. Real-time fluorescence quantitative PCR

[0070] Fluorescence quantitative kit qPCR SYBR Green Master Mix (No Rox) (CAT: 11201ES08) was used for quantitative expression detection on a PCR instrument, and 3 replicate wells were set. -ΔΔCt The miRNA expression was analyzed by PCR (U6 was used as internal reference). The miRNA primer sequences are shown in Table 3.

[0071] Table 3 miR-223 primer sequences

[0072]

[0073] The specific reaction conditions and reaction system of qRT-PCR are shown in Table 4 below:

[0074] Table 4 qRT-PCR

[0075]

[0076] VI. Bioinformatics Analysis

[0077] TargetScan predicts target genes, and their functions and possible biological pathways involved are completed by the KEGG database.

[0078] 7. Statistical Analysis

[0079] Statistical analysis was performed by GraphPad Prism, and the results were repeated three times. The quantitative data were expressed as mean ± standard deviation (X ± S). Independent sample t test was used for comparison between the two groups. The correlation coefficient r was used to evaluate the correlation between bile exosome miR-223 and clinical information. P < 0.05 was considered statistically significant. Among them, *** is P < 0.001, ** is P < 0.01, and * is P < 0.05.

[0080] 8. Results

[0081] The obtained bile exosomes were characterized by electron microscopy and NanoView fully automatic exosome fluorescence detection system. Figure 2 As shown, the extracted bile exosomes are saucer-shaped ( Figure 2 ), the average particle size is 66nm ( Figure 3 ); and rich in exosome characteristic markers such as CD63, CD81 and CD9 ( Figure 4 and Figure 5 ); demonstrating the successful acquisition of exosomes from bile.

[0082] The sequencing results showed that compared with non-AR patients, AR patients had significantly increased expression levels of 4 bile exosome miRNAs. Figure 6 and Table 5.

[0083] Table 5 Differential miRNAs among groups

[0084]

[0085] The expression level of miR-223 in bile exosomes of 20 AR and non-AR patients was detected by qRT-PCR. -ΔΔCt The method is to sort and analyze the data to obtain box plots (such as Figure 7 The results showed that miR-223 could be detected in the bile exosomes of both AR and non-AR patients, and its expression level in the bile samples of AR patients was significantly higher than that of non-AR patients, P<0.0001, which was statistically significant.

[0086] The ROC curve obtained by GraphPad Prism software analysis (such as Figure 8The area under the ROC curve (AUC) of miR-223 was 0.9475, with a specificity of 85% and a sensitivity of 90%. This shows that bile exosome miR-223 has good sensitivity, specificity and AUC, and has excellent performance in diagnosing acute rejection after liver transplantation, and can be used as a diagnostic marker for AR.

[0087] In this example, TargetScan was used to predict the target genes of bile exosome miRNAs that were significantly differentially expressed between AR and non-AR patients. The target gene prediction results of TargetScan software for differentially expressed miRNAs in bile exosomes of AR patients are shown in Table 6. The above target genes were further subjected to KEGG enrichment analysis, and the specific analysis results are shown in Fig. 9 .from Fig. 9 It can be seen that the pathways with higher enrichment of target genes predicted by bile exosome miRNAs differentially expressed in AR patients include protein processing in endoplasmic reticulum stress, axon guidance, etc.

[0088] Further correlation analysis was performed on the level of bile exosome miR-223 and other known clinical indicators. GraphPad Prism software was used to analyze miR-223 and the rejection activity index (RAI score) of AR patients in the same period, lymphocyte count in peripheral blood, alanine aminotransferase, γ-glutamyl transpeptidase, total bilirubin, albumin and prothrombin time. The results are shown in Table 7, showing that the level of bile exosome miR-223 was positively correlated with the RAI score of the transplanted liver, but not with the lymphocyte count, alanine aminotransferase, γ-glutamyl transpeptidase, total bilirubin, albumin and prothrombin time in peripheral blood.

[0089] Table 6 Differential miRNA target genes

[0090]

[0091] Table 7 Correlation between bile exosome miR-223 and clinical information

[0092]

[0093] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. Application of bile-derived exosomal miRNA as a molecular marker for the diagnosis of acute rejection after liver transplantation, characterized in that: The bile-derived exosomal miRNA is miR-223, and its nucleotide sequence is shown in SEQ ID NO.

1.

2. The use according to claim 1, characterized in that The nucleotide sequence of the reverse transcription primer of miR-223 is shown in SEQ ID NO.2; the nucleotide sequence of the forward amplification primer of miR-223 is shown in SEQ ID NO.3; and the nucleotide sequence of the reverse amplification primer of miR-223 is shown in SEQ ID NO.

4.

3. The use according to claim 1, characterized in that Bile-derived exosomes are saucer-shaped, with an average particle size of 66 nm, and are rich in CD63, CD81 and CD9 exosome characteristic markers.

4. The use according to claim 1, characterized in that The expression level of miR-223 is positively correlated with the incidence of acute rejection after liver transplantation.

5. The use according to claim 4, characterized in that The area under the ROC curve (AUC) of miR-223 was 0.9475, with a specificity of 85% and a sensitivity of 90%.

6. Use of a reagent for detecting the expression level of bile-derived exosome miRNA in the preparation of a diagnostic reagent / kit for acute rejection after liver transplantation, characterized in that: The bile-derived exosomal miRNA is miR-223, and its nucleotide sequence is shown in SEQ ID NO.

1.

7. The use according to claim 6, characterized in that The expression level of miR-223 is positively correlated with the incidence of acute rejection after liver transplantation.

8. A diagnostic product for acute rejection after liver transplantation, characterized in that: The diagnostic product includes reagents for detecting the expression of bile-derived exosomal miRNA; Among them, the bile-derived exosomal miRNA is miR-223, and its nucleotide sequence is shown in SEQ ID NO.

1.

9. The diagnostic product for acute rejection after liver transplantation according to claim 8, characterized in that: The diagnostic products include diagnostic reagents and diagnostic kits.

10. The diagnostic product for acute rejection after liver transplantation according to claim 8, characterized in that: The expression level of miR-223 was detected by real-time fluorescence quantitative PCR.